Evidence-Based Cannabis Education  ·  Peer-Reviewed Sources  ·  Compliance-Forward

For ProfessionalsAbout
Cannabis Information
Minor CannabinoidPsychoactive

THCV

Tetrahydrocannabivarin

Tetrahydrocannabivarin (THCV) is structurally similar to THC but with a propyl rather than pentyl side chain. It acts as a CB1 antagonist at low doses (appetite suppression) and a partial agonist at high doses. It shows promise for diabetes, obesity, and Parkinson's disease.

Mildly psychoactive at high doses only. At low-to-moderate doses, acts as a CB1 antagonist and may actually reduce THC's psychoactive effects.

Quick Facts

Molecular Formula
C₁₉H₂₆O₂
Molecular Weight
286.41 g/mol
Boiling Point
220°C (428°F)
Legal Status (U.S.)
Hemp-derived THCV (<0
Research Status
More advanced than most minor cannabinoids due to the 2016 Diabetes Care RCT

About THCV

Tetrahydrocannabivarin differs from THC by having a 3-carbon propyl side chain instead of a 5-carbon pentyl chain — a seemingly small structural difference that produces dramatically different pharmacological effects. THCV is found in higher concentrations in certain African landrace strains (particularly from South Africa and other equatorial regions).

THCV's most distinctive pharmacological feature is its dose-dependent receptor activity. At low doses, THCV acts as a CB1 receptor antagonist — blocking THC's effects and suppressing appetite. At higher doses, it becomes a CB1 partial agonist, producing mild psychoactive effects. It is also a CB2 partial agonist at all doses.

The metabolic effects of THCV are among the most clinically interesting findings in cannabinoid research. A 2016 randomized controlled trial published in Diabetes Care (n=62) found THCV significantly reduced fasting plasma glucose, improved pancreatic β-cell function, and increased adiponectin levels in type 2 diabetes patients — without the weight gain associated with some diabetes medications.

For Parkinson's disease, THCV has shown neuroprotective effects in animal models, reducing tremors and motor deficits. A 2011 study found THCV protected dopaminergic neurons in a 6-OHDA mouse model.

THCV's CB1 antagonism profile is reminiscent of rimonabant — a CB1 blocker that was approved in Europe for obesity but withdrawn due to psychiatric side effects. THCV's partial agonist activity at higher doses may give it a safer profile, but this requires clinical validation.

Receptor Affinity

  • CB1 antagonist (low dose)
  • CB1 partial agonist (high dose)
  • CB2 partial agonist
  • GPR55 agonist
  • TRPV1 agonist

Key Mechanisms

  • CB1 antagonism at low doses — appetite suppression, blocks THC psychoactivity
  • CB1 partial agonism at high doses — mild psychoactive effects
  • CB2 partial agonism — anti-inflammatory effects
  • Improves insulin sensitivity and pancreatic β-cell function
  • Neuroprotective effects via antioxidant and anti-inflammatory mechanisms
  • GPR55 agonism — bone density and metabolic effects
Evidence-Based

Clinical Uses & Evidence

Graded using a modified GRADE framework. Grade A = strong evidence; B = moderate; C = preliminary.

Type 2 Diabetes

Grade B

RCT (n=62) showed significant reduction in fasting glucose, improved β-cell function, increased adiponectin. Most robust human evidence for THCV.

Key study: Jadoon et al., Diabetes Care 2016

Obesity / Appetite Suppression

Grade C

CB1 antagonism mechanism supports appetite suppression. Animal studies confirm. No dedicated human obesity RCTs completed.

Key study: Riedel et al., Br J Pharmacol 2009

Parkinson's Disease

Grade C

Neuroprotective in 6-OHDA mouse model. Reduced tremors and protected dopaminergic neurons. No human trials.

Key study: García et al., Br J Pharmacol 2011

Epilepsy

Grade C

Anticonvulsant effects in animal models. May complement CBD in treatment-resistant epilepsy. No human RCTs.

Key study: Hill et al., Br J Pharmacol 2010

Side Effects

Mild psychoactivity at high dosesUncommon
Appetite suppression (may be undesirable in some patients)Common
Generally well-tolerated in clinical trialCommon

Drug Interactions

THCMild

CB1 antagonism at low doses may reduce THC psychoactivity and appetite stimulation

Antidiabetic medicationsModerate

Additive glucose-lowering effects; monitor for hypoglycemia

AntipsychoticsMild

CB1 antagonism may interact with antipsychotic mechanisms

Always consult a pharmacist or physician before combining cannabis with prescription medications. This list is not exhaustive.

Dosing Notes

Clinical trial used 5 mg twice daily for diabetes. Consumer products vary widely. The dose-dependent receptor switching (antagonist vs. agonist) makes dosing particularly important — low doses for metabolic effects, higher doses for psychoactive effects.

Dosing information is for educational purposes only. Consult a licensed healthcare provider for personalized guidance.

Legal Status

Hemp-derived THCV (<0.3% total THC) may be legal under the Farm Bill, but regulatory status is uncertain. Cannabis-derived THCV follows state cannabis laws. DEA has not issued specific guidance.

Key Sources

  • Efficacy and Safety of Cannabidivarin (CBDV) and Tetrahydrocannabivarin (THCV) in Type 2 Diabetes. Diabetes Care, 2016.
  • THCV as a neuroprotective agent in Parkinson's disease. British Journal of Pharmacology, 2011.
  • Cannabinoids and the gut: new developments and emerging concepts. Pharmacology & Therapeutics, 2012.